Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Quit Smoking Drugs Market Size Forecast: How Big Could The Market Get By 2030?
The quit smoking drugs market has witnessed rapid growth over recent years. It is anticipated to expand from $44.23 billion in 2025 to $50.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. This historical growth can be attributed to several factors, including heightened awareness of smoking hazards, an increase in smoking-related diseases, the availability of nicotine replacement therapies, government-led anti-smoking campaigns, and the expansion of pharmaceutical manufacturing in developing markets.
The quit smoking drugs market is projected to experience significant expansion in the coming years. This market is anticipated to reach $90.73 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.5%. Key factors contributing to this anticipated growth include advancements in digital health solutions, the increasing embrace of personalized medicine, the incorporation of AI into treatment monitoring, the broadening scope of telemedicine services, and the proliferation of wearable health monitoring devices. During the forecast period, prominent trends encompass personalized nicotine replacement therapies, mobile health (mHealth) and smoking cessation applications, prescription support facilitated by telemedicine, the combination of behavioral therapy with drug therapy, and wearable devices designed for craving monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Quit Smoking Drugs Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing incidence of smoking addiction is anticipated to stimulate the expansion of the quit-smoking drug market moving forward. Smoking involves the inhalation and exhalation of vapors from burning plant materials, including tobacco, marijuana, and hashish. Quit smoking drugs function as prescription medications to alleviate the urge to smoke by curbing tobacco cravings and managing nicotine withdrawal symptoms, thereby facilitating effective cessation. For instance, reports from November 2025 by the OECD (Organisation for Economic Co-operation and Development), an intergovernmental international organization based in France, revealed that 14.8% of people aged 15 and above smoked daily in 2023. The leading countries with the highest proportion of daily smokers included Türkiye, Hungary, and Greece, along with accession/partner countries Indonesia, Bulgaria, and China, where at least one in four individuals smoked daily. In 2023, an average of 18.5% of men smoked daily compared to 11.4% of women. Consequently, the growing prevalence of smoking addiction is significantly fueling the growth of the quit-smoking drug market.
Quit Smoking Drugs Market Segmentation: How Does The Market Break Down By Category?
The quit smoking drugs market covered in this report is segmented –
1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets
2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs
3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)
2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems
3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers
4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges
5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets
#Quit Smoking Drugs Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the quit smoking drugs market are concentrating on developing novel formulations and delivery methods, such as generic tablets, to expand their market leadership across regions and gain a competitive advantage. Generic varenicline tablets are non-branded forms of the medicine containing varenicline tartrate, which are bioequivalent to the original branded product and utilized for smoking cessation therapy. For instance, in January 2024, Lupin Limited, an India-based pharmaceutical company, introduced new Varenicline tablets in the United States, available in 0.5 mg and 1 mg strengths. These tablets represent the generic versions of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are employed to aid in smoking cessation treatment. Functioning as a partial agonist of the nicotinic acetylcholine receptor, varenicline operates by stimulating dopamine release, which can mitigate withdrawal symptoms and cravings linked to nicotine addiction. This dual mechanism allows it to decrease the pleasurable sensations of smoking while simultaneously offering some stimulation to minimize withdrawal effects.
Quit Smoking Drugs Market Competitive Overview And Top Companies
Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG
View The Full Quit Smoking Drugs Market Report:
Quit Smoking Drugs Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
